Kornimate/medical-research-clean huggingface dataset:
evaluate the possible efficacy and safety of empagliflozin in patient with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: •this study will be a randomized, controlled, parallel study. .to demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate uc using the montreal classification of severity of ulcerative colitis.

* it will be conducted on 60 patients having with mild to moderate degree uc divided into two groups: 1. group 1 (n=30): patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid). 2. group 2 (n=30): patients will receive conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid) and empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day). * the patient will be selected from the gastroenterology and endoscopy unit, internal medicine. . all patients will be subjected to the following: * complete history taking. * colonoscopy with intubation of the ileum and biopsies of affected and unaffected areas should be obtained to confirm the diagnosis of uc. * blood sample collection to assess: a) routine laboratory tests 1. complete blood picture (cbc). 2. liver functions (alt, ast, total and direct bilirubin). 3. kidney functions tests (urea, serum creatinine). 4. c-reactive protein. 5. fasting blood glucose. 6. urine analysis. b) specific laboratory tests 1. tumor necrosis factor alpha (tnf-α). 2. adenosine monophosphate kinase (9ampk). 3. fecal calprotectin. all patients will be assessed at baseline and after 4 months of therapy for all parameters

Eligibility criteria:
inclusion criteria: •patients with mild to moderate uc are diagnosed by history, clinical signs according to the montreal classification of severity of ulcerative colitis and( endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis. exclusion criteria: * other inflammatory bowel diseases (cd). * history of serious hypersensitivity to empagliflozin or any component of the formulation. * patients on dialysis. * severe renal impairment (egfr \<20 ml/minute/1.73m2) . * chronic urinary tract infection. * chronic genital infection.
clinical trial of ultrasound combined with computed tomography guided lumbar sympathetic ganglion block

Conditions: Pain, Chronic; Sympathetic Disorder; Ultrasound Therapy

Summary: to evaluate the safety and efficacy of ultrasound combined with ct-guided sympathetic ganglion block for refractory pain caused by sympathetic neuropathy of the lower extremities.

to evaluate the safety and efficacy of ultrasound combined with ct-guided sympathetic ganglion block for refractory pain caused by sympathetic neuropathy of the lower extremities. patients with lumbar sympathetic block were enrolled and randomized to a conventional ct-guided group and an ultrasound-guided ct-guided group. by comparing the traditional ct guided and ultrasound combined with ct guided two programs, the radiation dose, block success rate, treatment time, etc. received by patients with lumbar sympathetic block were observed to understand whether ultrasound combined with ct guidance is a way to reduce radiation exposure. under the premise of the dose, the method of blocking the success rate can still be guaranteed.

Eligibility criteria:
inclusion criteria: 1.18\~80 years old; 2.pain disorders requiring lumbar sympathetic block（such as,lower limb vascular disfunction,diabetic polyneuropathy,postherpetic neuralgia,complex regional pain syndrome i and ii,cancer related neuropathic pain including peripheral neuropathy caused by chemotherapy or other lower extremity sympathetic neuropathy）,conservative treatment for 3 months or longer can not be cured; 3.numerical rating score≥4. exclusion criteria: 1. body mass index\> 30 kg / m2; 2. history of internal fixation in posterior lumbar laminectomy or any serious anatomic variation, such as scoliosis and tumors; 3. history of lumbar sympathetic neurochemistry or thermal neurolysis; 4. pregnancy; 5. the puncture site is infected; 6. coagulation dysfunction; 7. allergic to local anesthetic or contrast agent; 8. cognitive impairment or inability to provide informed consent.

Keywords: lumbar sympathetic ultrasound
endoscopic resection for small rectal neuroendocrine tumors

Conditions: Rectal Neuroendocrine Tumor

Summary: according to clinical practice and relevant retrospective research data, both modified cap-assisted endoscopic mucosal resection (memr-c) and endoscopic mucosal resection with a ligation device(esmr-l) were reported to be effective for the treatment of small rectal neuroendocrine tumors (nets) . however, there is a lack of multicenter prospective studies to evaluate the advantages and disadvantages of memr-c and memr-l. memr-c is the modified esmr-l without submucosal injection.

we aimed to conduct a muticenter randomized controlled trial to compare memr-c with memr-l for the treatment of small rectal neuroendocrine tumors (nets) in ten tertiary hospitals in china.

Eligibility criteria:
inclusion criteria: 1. age from 18 to 80 years; 2. with a high suspicion or evidence of rectal net assessed using eus or colonoscopy; 3. with tumor size ≤10 mm assessed by colonoscopy; 4. plan to receive memr-c or memr-l treatment and provide written informed consent; exclusion criteria: 1. unable to tolerate memr-l or memr-c as assessed by the research team of each center; 2. complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation; 3. rectal net with lymph node metastasis or distant metastasis; 4. received resection of rectal neuroendocrine tumor by other surgical procedures; 5. multiple rectal neuroendocrine tumors; 6. vulnerable groups such as pregnant women or patients with mental disorders; 7. poor compliance, unable to cooperate with treatment.
the igf axis involvement in immune tumor microenvironment in ovarian cancer and its clinical significance

Conditions: Ovarian Cancer

Summary: the aim of this study is to evaluate the insulin-like growth factor (igf) axis involvement in the immune tumor microenvironment in ovarian cancer.


Eligibility criteria:
inclusion criteria: * women diagnosed with epithelium ovarian cancer who have undergone surgery exclusion criteria: * pregnant women
continuous versus intermittent enteral feeding in critically ill patients

Conditions: Nutrition Disorders

Summary: 1. nutritional support during critical illness is important to improve the clinical outcome of patients. recently, the apply of early enteral nutrition is recommend in critically ill patients on basis of data that enteral nutrition can be helpful to prevent the hospital-acquired infections. * however, in critically ill patients, the smooth progress of nutritional support is often hindered by gastrointestinal intolerance, underlying clinical condition, and temporal necessity of procedure or operation. * continuous feeding method, compared with intermittent feeding, is expected to reduce the risk of gastrointestinal intolerance, and improve the nutritional support, but this hypothesis is not supported by appropriate evidences. 2. we will elucidate to compare the efficacy and safety of the continuous feeding method in critically ill patients, compared with the intermittent feeding method. * prospective, randomized controlled study * primary outcome: the achievement rate of target nutritional goal within 7 days after the start of enteral nutrition * secondary outcome: gastrointestinal tolerance, in-icu/hospital mortality, frequency of hospital-acquired infection, icu/hospital length-of-stay, duration of mechanical ventilation


Eligibility criteria:
inclusion criteria: * adult patient admitted in the intensive care unit * age 20 years old or more * the enteral nutritional support is expected to be available within 48 hours after icu admission exclusion criteria: * previous abdominal surgery within 1 month * gastrointestinal bleeding, bowel obstruction, refractory vomiting/diarrhea * hypersensitivity to prokinetics, history of seizure or phechromocytoma * enteral feeding via enterostomy or gastrostomy * difficulty to insert or maintain nasogastric tube * need for specialized feeding (ex: hemodialysis diet, chronic renal failure diet, diabetes diet) * pregnancy
outcomes of mist for bph: a single-institution prospective study

Conditions: Benign Prostatic Hyperplasia

Summary: the investigators wish to perform a prospective study at the men's health clinic in winnipeg, manitoba to accomplish two goals: 1) prospectively describe 1 year outcomes for mist therapies performed at the clinic 2) perform a head to head comparison of rezum water vapor therapy vs the itind device in respect to symptom score improvement, uroflow parameters and side effect profile.

this prospective study is to be conducted at the men's health clinic in winnipeg, manitoba. all eligible patients who are to undergo rezum or itind procedure for bph/luts between march 2024 and march 2025 are to be included in the study. patient meeting inclusion criteria and exclusion criteria will be recruited to participate in this study. inclusion criteria: patients \> 18 years of age, undergoing rezum or itind treatment exclusion criteria: asa iii or higher, active uti within past week, age \< 18 years of age, no informed consent follow-up/data measurements will occur pre-procedure, immediately post procedure, 1 week, 6 weeks, and 3 months following procedure. at time of consultation pre-procedure, baseline symptom scores, uroflow parameters will be obtained. vas pain score is to be obtained during procedure, immediately post procedure, and at time of catheter or device removal 1 week post procedure. uroflow parameters and symptoms scores will be again measured at 6 weeks and 3 months.

Eligibility criteria:
inclusion criteria: * patients \> 18 years of age undergoing rezum or itind treatment exclusion criteria: * asa 3 or higher, active uti within past week, age \< 18 years of age, no informed consent
short- and long-term behavioral, cognitive and motor outcomes of frameless deep brain stimulation in patients with parkinson's disease: a prospective observational study

Conditions: Parkinson Disease

Summary: the main objective of the study is to evaluate the improvement in quality of life after deep brain stimulation surgery with frameless technique by comparing the pdq-39 scale score at baseline (before surgery) and one year after surgery.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease according to movement disorder society (mds) criteria; * patients who are candidates for deep brain stimulation intervention, according to the international criteria of the "core assessment program for surgical interventional therapies in parkinson's disease" (capsit-pd). exclusion criteria: - patients unable to give informed consent.
laser induced changes to innervation and vascularisation of psoriatic skin

Conditions: Psoriasis Vulgaris

Summary: the researchers investigate the effect of a treatment with selective photothermolysis using a 595 nm pulsed dye laser on the blood vessel density and the nerve fibre density of a psoriatic lesion. by comparing tissue samples collected before and after two treatments, the researchers determine the relative effect of laser therapy on the (hyper)innervation of psoriatic skin.

vascular laser therapy for psoriasis seems to achieve a remarkably long treatment-free duration of remission. but why would sub-second heating of the blood vessels of the skin result in a year-long resolution of an infamously stubborn condition? unraveling the mechanism of action of laser therapy would not only allow for the improvement of existing laser therapy protocols but also, could open the door to a whole new range of interventions offering quasi-permanent solutions for patients. there is a high need for such enduring therapies: psoriasis is both, a common and a costly skin condition. it affects between 1% and 9% of the population and has a very severe impact on the quality of life of the patient. it's chronic character implies lifelong treatment, and the associated risks and effort this project aims to assess the effect of laser therapy on the blood vessels and (peripheral) innervation of psoriasis plaques. the primary objective is to quantify the regression and recovery of nerves compared to blood vessels. the researchers hypothesize that the recovery of nerves after selective photo thermolysis (spt) is decreased compared to the recovery of blood vessels.

Eligibility criteria:
inclusion criteria: * 18 - 69 years of age * psoriasis vulgaris * skin type i - iii * minimal surface of lesion of 3 cm2 * contralateral psoriasis vulgaris lesions located on chest, back, or upper legs exclusion criteria a potential subject who meets any of the following criteria will be excluded from participation in this study if: * the participant uses other treatments (than laser therapy) during the study or two weeks before the start of the study that are known to affect psoriasis * the participant suffers from any known neurological, vascular, or immunological condition other than psoriasis. * the participant is allergic to lidocaine
sedative premedication in coronary angiography

Conditions: Coronary Angiography; Sedative Premedication

Summary: evaluation of the possible positive effect of sedative premedication prior to coronary angiography in regards to pain and anxiety.

coronary angiography is an invasive procedure that can cause patient discomfort. sedative premedication before coronary angiography could be used to reduce anxiety and pain, but evidence is lacking. previous trials were predominantly conducted in men and in coronary interventions with femoral access. recently, radial access has become the preferred route for performing coronary angiograms (rival trial) in this setting, sedative premedication could be of interest to reduce radial spasms, patient anxiety and pain.

Eligibility criteria:
inclusion criteria: * elective coronary angiography exclusion criteria: * planned pci * use of sedative medication at home * use of alcohol

Keywords: coronary angiography premedication pain anxiety
pharmacokinetics of tranexamic acid (txa) in children undergoing repair of congenital heart defects utilizing cardiopulmonary bypass

Conditions: Congenital Heart Disease

Summary: the purpose of this study is to measure blood levels of txa in children having cardiac surgery which requires cardiopulmonary bypass. txa is used to reduce bleeding during surgery. this study will help determine if the current dosing of txa results in therapeutic blood levels.


Eligibility criteria:
inclusion criteria: * congenital heart disease requiring surgical repair with cardiopulmonary bypass exclusion criteria: * children weighing over 20 kg * family does not want to participate in the study
gvax® vaccine for prostate cancer vs docetaxel & prednisone in patients with metastatic hormone-refractory prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to compare the duration of survival between gvax® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate * metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy * detectable metastases * any gleason score * ecog performance status 0-2 exclusion criteria: * prior treatment with chemotherapy * prior immunotherapy * prior treatment with gene therapy * significant cancer related pain

Keywords: prostate cancer metastatic hormone-refractory gvax chemotherapy taxotere docetaxel prednisone vaccine allogeneic cells advanced prostate cancer
an observational study to evaluate neoadjuvant nivolumab (opdivo®) in combination with platinum-based chemotherapy in non-metastatic non-small cell lung cancer participants in germany

Conditions: Resectable Non-small Cell Lung Cancer

Summary: the purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (nsclc) in germany


Eligibility criteria:
inclusion criteria: * aged 18 years or older * diagnosis of non-metastatic non-small cell lung cancer with tumor programmed death-ligand 1 (pd-l1) expression level of 1% or more (tumor proportion score (tps); according to label approved in the european union) * decision to initiate a neoadjuvant treatment with nivolumab plus platinum-based chemotherapy for treatment of non-small cell lung cancer according to current summary of product characteristics and independent of the study * willing to complete patient-reported outcome questionnaires and sufficient understanding of the german language * signed written informed consent * other criteria according to current summary of product characteristics exclusion criteria: * current primary diagnosis of cancer other than non-small cell lung cancer that requires systemic or other treatment * other contraindications according to current summary of product characteristics
the efficacy and tolerability of modafinil for fatigue and daytime sleepiness in cancer patients: preliminary study

Conditions: Fatigue

Summary: open-pilot study for the efficacy and tolerability of modafinil on the fatigue and somnolence in cancer-patients.

this is an open-pilot study for the efficacy and tolerability of modafinil on the fatigue and somnolence in cancer-patients. patients with moderate to severe cancer-related fatigue will be treated with modafinil for 4 weeks and psychological tests including self-questionnaire, cognitive test, sleep-wake cycle, quantitative electroencephalogram(qeeg) will be applied pre- and post-treatment.

Eligibility criteria:
inclusion criteria: * solid cancer patient * age of 20-65 years old * subjects who scored =4 or \>4 on the brief fatigue inventory * subjects with informed consent exclusion criteria: * metastatic cancer(stage iv) * with psychotic symptoms such as delusion and hallucination or with suicidal risk * with delirium or dementia * current medication of cognitive enhancer or psychostimulant uncontrolled medical illness * current medications that are contraindicated or not recommended for co-administration with modafinil
co-parent: covid-19 - parent action in response to emotions and needs for treatment

Conditions: Anxiety; Depression; Traumatic Stress Disorder

Summary: the purpose of this research study is to collect information to better understand caregiver responses to covid-19 stress and to help caregivers cope with these stressors.


Eligibility criteria:
inclusion criteria: * consent to participate via redcap * indicate a mild or greater elevation on screening measures of anxiety, depression and/or traumatic stress * have a child between 6 and 13 years * speak/read english or spanish fluently exclusion criteria: * reported severe mental illness (e.g., bipolar disorder, schizophrenia, an intellectual disability, psychosis, alcohol use disorder, substance use disorder) or hospitalization for mental health concerns or suicide attempt. * reported prior arrest for child endangerment, child abuse or child neglect, or prior investigation by the florida department of children and families (dcf) * may be excluded if the severity of current mental illness is such that outpatient, weekly group treatment would be considered inappropriate

Keywords: covid-19
effect of aerobic training in patients with oculopharyngeal muscular dystrophy

Conditions: Oculopharyngeal Muscular Dystrophy

Summary: the investigators want to investigate if patients with oculopharyngeal muscular dystrophy can improve fitness by home-training on a cycle ergometer 30 minute, 3 times a week for 10 weeks. participants will be evaluated on maximal oxygen consumption and maximal workload measured by an incremental test at baseline and at the end of the exercise period.


Eligibility criteria:
inclusion criteria: * danish patients with oculopharyngeal muscular dystrophy exclusion criteria: * patients who are too week to train on an cycle-ergometer for 10 weeks * patients with other health issues wich confound the interpretation of the efficacy.
a study to assess the safety, efficacy, and pharmacokinetics of miricorilant (cort118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications

Conditions: Antipsychotic-induced Weight Gain (AIWG)

Summary: this phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (pk) of miricorilant (cort118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications.

this is a randomized, double-blind, placebo-controlled study that will assess the safety, efficacy, and pk of miricorilant in obese patients with schizophrenia or bipolar disorder who are currently taking oral or injectable atypical antipsychotic medication. patients who meet the criteria for the study cort118335-876 will be randomized on day 1 to receive 600 mg miricorilant or placebo for 12 weeks.

Eligibility criteria:
inclusion criteria: * have a diagnosis of schizophrenia or bipolar disorder * are currently taking oral or injectable atypical antipsychotic medication (except clozapine) and must have documented weight gain while on these medications * must be on a stable dose of medication for 1 month prior to screening * are able to successfully complete placebo tablet swallow test * have a bmi ≥30 kg/m\^2. exclusion criteria: * have a history of a medical condition affecting body weight (eg, poorly controlled hyper- or hypothyroidism; eating disorder such as anorexia, bulimia, or binge eating; or polycystic ovary syndrome) * have poorly controlled diabetes mellitus * have poorly controlled hypertension * have a history of symptomatic hypotension * have a history of orthostatic hypotension.

Keywords: antipsychotic-induced weight gain (aiwg) obesity weight gain mental disorders schizophrenia risperidone quetiapine olanzapine bipolar disorder